Literature DB >> 30046535

Ocular hypertension in patients with central/hemicentral retinal vein occlusions: cumulative prevalence and management.

Dan Călugăru1, Mihai Călugăru1, Ştefan Ţălu2.   

Abstract

AIM: To prospectively evaluate the cumulative prevalence and the management of ocular hypertension (OH) in patients with unilateral acute central/hemicentral retinal vein occlusions (C/HCRVOs) over the course of 3y.
METHODS: The study included 57 patients with unilateral acute C/HCRVOs. All patients underwent a comprehensive ophthalmological examination of both eyes. OH associated with C/HCRVO in patients showing a score >5% for the risk of conversion to primary open angle glaucoma (POAG) was treated with OH medication. The treatment aimed for a decrease in intraocular pressure (IOP) to <21 mm Hg with a >22% reduction from the initial values. The cumulative prevalence of OH and the effectiveness of treatment assessed by the cumulative prevalence of conversion from OH to POAG, were estimated.
RESULTS: Fifteen patients had OH associated with C/HCRVOs, the cumulative prevalence of OH was 29.4% (95% confidence interval, 16.9-41.9). The mean value of the risk score of OH conversion to POAG for the 5 subsequent years was 11.7%±5.4%. The IOP significantly decreased from 25.67±2.16 mm Hg to 18.73±2.96 mm Hg. None of the OH patients converted to POAG during the follow-up period.
CONCLUSION: The increased cumulative prevalence of OH in C/HCRVO patients indicates that OH is a risk factor for the appearance of venous occlusion. Patients with OH associated with C/HCRVO must be considered to be at high risk for conversion to POAG. Treatment with OH medications prevented conversion to POAG during the 3-year follow-up.

Entities:  

Keywords:  acute central/hemicentral retinal vein occlusion; intraocular pressure; ocular hypertension; primary open-angle glaucoma; risk factor

Year:  2018        PMID: 30046535      PMCID: PMC6048337          DOI: 10.18240/ijo.2018.07.16

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  21 in total

Review 1.  Ocular vascular occlusive disorders: natural history of visual outcome.

Authors:  Sohan Singh Hayreh
Journal:  Prog Retin Eye Res       Date:  2014-04-21       Impact factor: 21.198

2.  Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the Ranidex study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-25       Impact factor: 3.117

Review 3.  Ocular Hypertension Following Intravitreal Antivascular Endothelial Growth Factor Therapy: Review of the Literature and Possible Role of Nitric Oxide.

Authors:  R Grant Morshedi; Aaron M Ricca; Barbara M Wirostko
Journal:  J Glaucoma       Date:  2016-03       Impact factor: 2.503

4.  Comment on: 'Combination of peripheral laser photocoagulation with intravitreal bevacizumab in naive eyes with macular edema secondary to CRVO: prospective randomized study'.

Authors:  D Călugăru; M Călugăru
Journal:  Eye (Lond)       Date:  2016-06-10       Impact factor: 3.775

5.  Delaying treatment of ocular hypertension: the ocular hypertension treatment study.

Authors:  Michael A Kass; Mae O Gordon; Feng Gao; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John K Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson
Journal:  Arch Ophthalmol       Date:  2010-03

6.  Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study.

Authors:  Donald L Budenz; Douglas R Anderson; William J Feuer; Julia A Beiser; Joyce Schiffman; Richard K Parrish; Jody R Piltz-Seymour; Mae O Gordon; Michael A Kass
Journal:  Ophthalmology       Date:  2006-09-25       Impact factor: 12.079

Review 7.  What We Have Learned From the Ocular Hypertension Treatment Study.

Authors:  Mae O Gordon; Michael A Kass
Journal:  Am J Ophthalmol       Date:  2018-03-01       Impact factor: 5.258

8.  The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

Authors:  Michael A Kass; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2002-06

9.  The European glaucoma prevention study design and baseline description of the participants.

Authors:  Stefano Miglior; Thierry Zeyen; Norbert Pfeiffer; Jose Cunha-Vaz; Valter Torri; Ingrid Adamsons
Journal:  Ophthalmology       Date:  2002-09       Impact factor: 12.079

10.  Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.

Authors:  M Cristina Leske; Anders Heijl; Mohamed Hussein; Bo Bengtsson; Leslie Hyman; Eugene Komaroff
Journal:  Arch Ophthalmol       Date:  2003-01
View more
  1 in total

Review 1.  Intraocular pressure modifications in patients with acute central/hemicentral retinal vein occlusions.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Int J Ophthalmol       Date:  2021-06-18       Impact factor: 1.779

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.